Gianluca Veggiani

Gianluca Veggiani serves as Assistant Professor in the Department of Pathobiological Sciences at Louisiana State University's School of Veterinary Medicine, where he leads research at the intersection of protein engineering and disease mechanisms. His work focuses on developing innovative diagnostic and therapeutic platforms for cancer and infectious diseases through nano-immunoengineering approaches.

Dr. Veggiani's educational foundation includes:

• PhD, University of Oxford (England), 2017
• MSc, University of Padua (Italy), 2011
• BSc, University of Padua (Italy), 2008

His laboratory specializes in rewiring cellular signaling pathways through nano-immunoengineering, biochemical and structural methods, with emphasis on malignant transformation and viral infection responses. Key methodologies include molecular evolution (phage-display) and CRISPR/Cas9 gene editing for cancer biomarker discovery and immunotherapy development, creating direct pathways to novel diagnostics and antiviral solutions.

Publication analysis reveals a concentrated focus on protein domain engineering (SH2, chromodomains, ubiquitin) for biomedical applications, with 2022-2023 output highlighting cancer diagnostics and SARS-CoV-2 evolution research. His work consistently bridges fundamental protein science with translational medical applications, particularly in cancer cell isolation and epigenetic regulation.

Dr. Veggiani's scientific contributions have been recognized through:

• H2i Pitch Perfect Competition for innovative healthcare solutions (2020)
• Newsholme graduate prize for Biochemistry academic distinction (2016)
• Medical Research Council Doctoral Training Partnership (2015-2016)
• Merton College Scholarship, University of Oxford (2012-2015)

His 2020 H2i award demonstrates successful translation of research into fundable healthcare innovations. The lab provides students with interdisciplinary training in protein engineering and disease modeling, fostering skills applicable to both academic and industry careers in biotechnology.

Dr. Veggiani maintains active international collaborations, particularly with UK and Canadian institutions, driving his research in protein nanotechnology for cancer diagnostics and antiviral development. His work on bacterial superglue platforms (Spy systems) exemplifies the lab's focus on creating ultrastable protein interactions for medical applications.